Diego M. Cantoni

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.

Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.

Journal: Emerging microbes & infections
Published: May 06, 2025

Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic.

Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic.

Journal: Nature microbiology
Published: April 17, 2024

Serological evidence of virus infection in Eidolon helvum fruit bats: implications for bushmeat consumption in Nigeria.

Serological evidence of virus infection in Eidolon helvum fruit bats: implications for bushmeat consumption in Nigeria.

Journal: Frontiers in public health
Published: August 25, 2023

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Journal: NPJ vaccines
Published: July 29, 2023

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.

Journal: Frontiers in immunology
Published: March 11, 2023

Low hanging fruit for combatting SARS-CoV-2?

Low hanging fruit for combatting SARS-CoV-2?

Journal: EMBO reports
Published: February 10, 2023

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Journal: Frontiers in immunology
Published: December 07, 2022

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.

Journal: Scientific reports
Published: November 07, 2022

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.

Journal: Vaccines
Published: November 04, 2022

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.

Journal: The journal of allergy and clinical immunology. Global
Published: October 17, 2022

Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Journal: Nature microbiology
Published: September 16, 2022

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies.

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies.

Journal: The Lancet. Microbe
Published: August 31, 2022
Showing 1-12 of 36

Last Updated: 09/26/2026